NBP
HEALTHCARENovaBridge Biosciences.
$2.25-0.13 (-5.46%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NBP Today?
No stock-specific AI insight has been generated for NBP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.85$6.79
$2.25
Fundamentals
Market Cap$260M
P/E Ratio—
EPS$-0.48
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding115.6M
NBP News
19 articles- NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline ValueYahoo Finance·Apr 22, 2026
- NovaBridge Reports Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Apr 7, 2026
- NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric CancerYahoo Finance·Mar 16, 2026
- NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD StudyYahoo Finance·Mar 9, 2026
- NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026Yahoo Finance·Mar 3, 2026
- NovaBridge to Present at the Leerink Partners 2026 Global Healthcare ConferenceYahoo Finance·Mar 2, 2026
- NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech PlatformYahoo Finance·Feb 19, 2026
- NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric CancerYahoo Finance·Feb 17, 2026
- Amazon downgraded, Roblox upgraded: Wall Street's top analyst callsYahoo Finance·Feb 6, 2026
- Insider Spends US$5.1m Buying More Shares In NovaBridge BiosciencesYahoo Finance·Feb 5, 2026
- NovaBridge Announces Open Market Purchases by Executive Chairman, Fu WeiYahoo Finance·Jan 20, 2026
- Is There An Opportunity With NovaBridge Biosciences' (NASDAQ:NBP) 40% Undervaluation?Yahoo Finance·Jan 8, 2026
- NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric CancerYahoo Finance·Jan 6, 2026
- NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026Yahoo Finance·Dec 30, 2025
- Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In GrowthYahoo Finance·Dec 19, 2025
- NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IOYahoo Finance·Dec 11, 2025
- NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IOYahoo Finance·Dec 4, 2025
- NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 ForwardYahoo Finance·Nov 21, 2025
- NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian CountriesYahoo Finance·Oct 30, 2025
All 19 articles loaded
Price Data
Open$2.42
Previous Close$2.38
Day High$2.56
Day Low$2.37
52 Week High$6.79
52 Week Low$0.85
52-Week Range
$0.85$6.79
$2.25
Fundamentals
Market Cap$260M
P/E Ratio—
EPS$-0.48
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding115.6M
About NovaBridge Biosciences.
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is headquartered in Rockville, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—